GlaxoSmithKline Biologicals (GSK) is advancing its net-zero objectives by collaborating with ABB to enhance energy efficiency at its vaccine production site in Tuas South, Singapore. This upgrade involves the deployment of 65 ABB IE5 ultra-premium efficiency synchronous reluctance motors (SynRM) and variable speed drives (VSDs).
The improvements are projected to reduce electricity usage by 615 MWh annually, cut CO₂ emissions by 246 tonnes, and save approximately USD 130,000 in energy costs, surpassing the site’s decarbonisation targets by 25%.
The initiative is a testament to GSK’s commitment to reducing greenhouse gas emissions by 80% by 2030. Singapore continues to serve as a pivotal hub for sustainable pharmaceutical innovation. The project, rolled out in phases from September to December 2024, marks the debut of ABB VSDs at the Tuas South facility. These VSDs adjust motor speed based on system demand, akin to controlling a car’s accelerator, thus enhancing energy efficiency by at least 25%.
William Tan, Sustainability Manager at GSK Tuas Singapore, highlighted the strategic importance of the upgrade: “ABB’s solution helped us surpass our original emissions reduction target at Tuas South, delivering financial savings and reliability improvements while cutting 246 tonnes of CO₂ emissions annually. This is a tangible example of how we are translating our 2045 net-zero ambition into action.”
Globally, GSK is pursuing an 80% reduction in greenhouse gas emissions from a 2020 baseline by 2030, aiming for full value chain net-zero by 2045. The Tuas South facility has initiated a series of energy-saving measures, focusing significantly on optimising HVAC systems. By utilising ABB’s SynRM and VSD technologies, along with advanced energy reporting, GSK is on a path to validate its sustainability goals with measurable outcomes.
Mayly May, Energy Efficiency Market Development Manager at ABB Motion Services, stated, “Working with GSK challenged us to deliver more than just equipment. We are proud to help them unlock significant savings and environmental gains via a thorough energy efficiency strategy, laying the foundation for deeper collaboration in sustainable pharmaceutical manufacturing.”
